

REMICADE-maintenance experienced elevations in ALT at >1 to <3 times the ULN compared to 34% of patients treated with placebo-maintenance. ALT elevations  $\geq 3$  times the ULN were observed in 5% of patients who received REMICADE-maintenance compared with 4% of patients who received placebo-maintenance. ALT elevations  $\geq 5$  times ULN were observed in 2% of patients who received REMICADE-maintenance compared to none in patients treated with placebo-maintenance. In UC clinical trials (median follow up 30 weeks. Specifically, the median duration of follow-up was 30 weeks for placebo and 31 weeks for REMICADE), 17% of patients receiving REMICADE experienced elevations in ALT at >1 to <3 times the ULN compared to 12% of patients treated with placebo. ALT elevations  $\geq 3$  times the ULN were observed in 2% of patients who received REMICADE compared with 1% of patients who received placebo. ALT elevations  $\geq 5$  times ULN were observed in <1% of patients in both REMICADE and placebo groups. In an AS clinical trial (median follow up 24 weeks for placebo group and 102 weeks for REMICADE group) 51% of patients receiving REMICADE experienced elevations in ALT at >1 to <3 times the ULN compared to 15% of patients treated with placebo. ALT elevations  $\geq 3$  times the ULN were observed in 10% of patients who received REMICADE compared to none in patients who received placebo. ALT elevations  $\geq 5$  times ULN were observed in 4% of patients who received REMICADE compared to none in patients treated with placebo. In a PsA clinical trial (median follow up 39 weeks for REMICADE group and 18 weeks in placebo group) 50% of patients receiving REMICADE experienced elevations in ALT at >1 to <3 times the ULN compared to 16% of patients treated with placebo. ALT elevations  $\geq 3$  times the ULN were observed in 7% of patients who received REMICADE compared to none in patients who received placebo. ALT elevations  $\geq 5$  times ULN were observed in 2% of patients who received REMICADE compared to none in patients treated with placebo. In PsO clinical trials, (ALT values are obtained in 2 phase 3 psoriasis studies with median follow-up of 50 weeks for REMICADE and 16 weeks for placebo). 49% of patients receiving REMICADE experienced elevations in ALT at >1 to <3 times the ULN compared to 24% of patients treated with placebo. ALT  $\geq 3 \times$  ULN were observed in 8% of patients who received REMICADE compared to <1% who received placebo. ALT elevations  $\geq 5 \times$  ULN were observed in 3% of patients who received REMICADE compared to none in patients treated with placebo. **Adverse Reactions in Pediatric Crohn's Disease** There were some differences observed in the adverse reactions observed in the pediatric patients receiving REMICADE compared to those observed in adults with CD. The following adverse events were reported more commonly in 103 randomized pediatric CD patients administered 5 mg/kg REMICADE through 54 weeks than in 385 adult CD patients receiving a similar treatment regimen: anemia (11%), blood in stool (10%), leukopenia (9%), flushing (9%), viral infection (8%), neutropenia (7%), bone fracture (7%), bacterial infection (6%), and respiratory tract allergic reaction (6%). Infections were reported in 56% of randomized pediatric patients in Study Peds Crohn's and in 50% of adult patients in Study Crohn's I. In Study Peds Crohn's, infections were reported more frequently for patients who received every 8 week as opposed to every 12 week infusions (74% and 38%, respectively), while serious infections were reported for 3 patients in the every 8 week and 4 patients in the every 12 week maintenance treatment group. The most commonly reported infections were upper respiratory tract infection and pharyngitis, and the most commonly reported serious infection was abscess. Pneumonia was reported for 3 patients, (2 in the every 8 week and 1 in the every 12 week maintenance treatment groups). Herpes zoster was reported for 2 patients in the every 8 week maintenance treatment group. In Study Peds Crohn's, 18% of randomized patients experienced one or more infusion reactions, with no notable difference between treatment groups. Of the 112 patients in Study Peds Crohn's, there were no serious infusion reactions, and 2 patients had non-serious anaphylactoid reactions. Antibodies to REMICADE developed in 3% of pediatric patients in Study Peds Crohn's. Elevations of ALT up to 3 times the upper limit of normal (ULN) were seen in 18% of pediatric patients in CD clinical trials; 4% had ALT elevations  $\geq 3 \times$  ULN, and 1% had elevations  $\geq 5 \times$  ULN. (Median follow-up was 53 weeks.) The most common serious adverse events reported in the post-marketing experience in children were infections (some fatal) including opportunistic infections and tuberculosis, infusion reactions, and hypersensitivity reactions. Serious adverse events in the post-marketing experience with REMICADE in the pediatric population have also included malignancies, including hepatosplenic T-cell lymphomas (see *Boxed WARNINGS* and *WARNINGS*), transient hepatic enzyme abnormalities, lupus-like syndromes, and the development of autoantibodies. **Adverse Reactions in Psoriasis Studies** During the placebo-controlled portion across the three clinical trials up to Week 16, the proportion of patients who experienced at least 1 SAE (defined as resulting in death, life threatening, requires hospitalization, or persistent or significant disability/incapacity) was 1.7% in the 3 mg/kg REMICADE group, 3.2% in the placebo group, and 3.9% in the 5 mg/kg REMICADE group. Among patients in the 2 Phase 3 studies, 12.4% of patients receiving REMICADE 5 mg/kg every 8 weeks through one year of maintenance treatment experienced at least 1 SAE in Study I. In Study II, 4.1% and 4.7% of patients receiving REMICADE 3 mg/kg and 5 mg/kg every 8 weeks, respectively, through one year of maintenance treatment experienced at least 1 SAE. One death due to bacterial sepsis occurred 25 days after the second infusion of 5 mg/kg REMICADE. Serious infections included sepsis, and abscesses. In Study I, 2.7% of patients receiving REMICADE 5 mg/kg every 8 weeks through 1 year of maintenance treatment experienced at least 1 serious infection. In Study II, 1.0% and 1.3% of patients receiving REMICADE 3 mg/kg and 5 mg/kg, respectively, through 1 year of treatment experienced at least 1 serious infection. The most common serious infections (requiring hospitalization) were abscesses (skin, throat, and peri-rectal) reported by 5 (0.7%) patients in the 5 mg/kg REMICADE group. Two active cases of tuberculosis were reported: 6 weeks and 34 weeks after starting REMICADE. In placebo-controlled portion of the psoriasis studies, 7 of 1123 patients who received REMICADE at any dose were diagnosed with at least one NMSC compared to 0 of 334 patients who received placebo. In the psoriasis studies, 1% (15/1373) of patients experienced serum sickness or a combination of arthralgia and/or myalgia with fever, and/or rash, usually early in the treatment course. Of these patients, 6 required hospitalization due to fever, severe myalgia, arthralgia, swollen joints, and immobility. **Other Adverse Reactions** Safety data are available from 4779 REMICADE-treated adult patients, including 1304 with RA, 1106 with CD, 484 with UC, 202 with AS, 293 with PsA, 1373 with plaque PsO and 17 with other conditions. (For information on other adverse reactions in pediatric patients, see *ADVERSE REACTIONS, Adverse Reactions in Pediatric Crohn's Disease*.) Adverse events reported in  $\geq 5\%$  of all patients with RA receiving 4 or more infusions are listed below. The types and frequencies of adverse reactions observed were similar in REMICADE-treated RA, AS, PsA, plaque PsO and CD patients except for abdominal pain, which occurred in 26% of REMICADE-treated patients with CD. In the CD studies, there were insufficient numbers and duration of follow-up for patients who never received REMICADE to provide meaningful comparisons. The percentages of adverse events for placebo-treated patients (n=350; average weeks of follow-up 59) and REMICADE-treated patients (n=1129; average weeks of follow-up 66), respectively, are: *Gastrointestinal*: Nausea: 20, 21; Abdominal pain: 8, 12; Diarrhea: 12, 12; Dyspepsia: 7, 10; *Respiratory*: Upper respiratory tract infection: 25, 32; Sinusitis: 8, 14; Pharyngitis: 8, 12; Coughing: 8, 12; Bronchitis: 9, 10; Rhinitis: 5, 8; *Skin and appendages disorders*: Rash: 5, 10; Pruritus: 2, 7; *Body as a whole—general disorders*: Fatigue: 7, 9; Pain: 7, 8; *Resistance mechanism disorders*: Fever: 4, 7; Moniliasis: 3, 5; *Central and peripheral nervous system disorders*: Headache: 14, 18; *Musculoskeletal system disorders*: Back pain: 5, 8; Arthralgia: 7, 8; *Urinary system disorders*: Urinary tract infection: 6, 8; *Cardiovascular disorders, general*: Hypertension: 5, 7. Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of a drug cannot be directly compared to rates in clinical trials of another drug and may not predict the rates observed in broader patient populations in clinical practice. The most common serious adverse events observed in clinical trials were infections (see *ADVERSE REACTIONS, Infections*). Other serious, medically relevant adverse events  $\geq 0.2\%$  or clinically significant adverse events by body system were as follows: *Body as a whole*: allergic reaction, diaphragmatic hernia, edema, surgical/procedural sequelae; *Blood*: pancytopenia; *Cardiovascular*: circulatory failure, hypotension, syncope; *Gastrointestinal*: constipation, gastrointestinal hemorrhage, ileus, intestinal obstruction, intestinal perforation, intestinal stenosis, pancreatitis, peritonitis, proctalgia; *Central & Peripheral Nervous*: meningitis, neuritis, peripheral neuropathy, dizziness; *Heart Rate and Rhythm*: arrhythmia, bradycardia, cardiac arrest, tachycardia; *Liver and Biliary*: biliary pain, cholecystitis, cholelithiasis, hepatitis; *Metabolic and Nutritional*: dehydration; *Musculoskeletal*: intervertebral disk herniation, tendon disorder; *Myo-, Endo-, Pericardial, and Coronary Valve*: myocardial infarction; *Platelet, Bleeding, and Clotting*: thrombocytopenia; *Neoplasms*: basal cell, breast, lymphoma; *Psychiatric*: confusion, suicide attempt; *Red Blood Cell*: anemia, hemolytic anemia; *Reproductive*: menstrual irregularity; *Resistance Mechanism*: cellulitis, sepsis, serum sickness; *Respiratory*: adult respiratory distress syndrome, lower respiratory tract infection (including pneumonia), pleural effusion, pleurisy, pulmonary edema, respiratory insufficiency; *Skin and Appendages*: increased sweating, ulceration; *Urinary*: renal calculus, renal failure; *Vascular (Extracardiac)*: brain infarction, pulmonary embolism, thrombophlebitis; *White Cell and Reticuloendothelial*: leukopenia, lymphadenopathy. **Post-marketing Adverse Events** The following adverse events, some with fatal outcome, have been reported during post-approval use of REMICADE: neutropenia (see *WARNINGS, Hematologic Events*), interstitial lung disease (including pulmonary fibrosis/ interstitial pneumonitis and very rare rapidly progressive disease), idiopathic thrombocytopenic purpura, thrombotic thrombocytopenic purpura, pericardial effusion, systemic and cutaneous vasculitis, erythema multiforme, Stevens-Johnson Syndrome, toxic epidermal necrolysis, Guillain-Barré syndrome, psoriasis (including new onset and pustular, primarily palmar/plantar), transverse myelitis, and neuropathies (additional neurologic events have also been observed, see *WARNINGS, Neurologic Events*) and acute liver failure, jaundice, hepatitis, and cholestasis (see *WARNINGS, Hepatotoxicity*). Because these events are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to REMICADE exposure. The following serious adverse events have been reported in the post-marketing experience in children: infections (some fatal) including opportunistic infections and tuberculosis, infusion reactions, and hypersensitivity reactions. Serious adverse events in the post-marketing experience with REMICADE in the pediatric population have also included malignancies, including hepatosplenic T-cell lymphomas (see *Boxed WARNINGS* and *WARNINGS*), transient hepatic enzyme abnormalities, lupus-like syndromes, and the development of autoantibodies. **OVERDOSAGE**: Single doses up to 20 mg/kg have been administered without any direct toxic effect. In case of overdosage, it is recommended that the patient be monitored for any signs or symptoms of adverse reactions or effects and appropriate symptomatic treatment instituted immediately. **Administration Instructions Regarding Infusion Reactions** Adverse effects during administration of REMICADE have included flu-like symptoms, headache, dyspnea, hypotension, transient fever, chills, gastrointestinal symptoms, and skin rashes. Anaphylaxis might occur at any time during REMICADE infusion. Approximately 20% of REMICADE-treated patients in all clinical trials experienced an infusion reaction compared with 10% of placebo-treated patients (see *ADVERSE REACTIONS, Infusion-related Reactions*). Prior to infusion with REMICADE, premedication may be administered at the physician's discretion. Premedication could include antihistamines (anti-H1 +/- anti-H2), acetaminophen and/or corticosteroids. During infusion, mild to moderate infusion reactions may improve following slowing or suspension of the infusion, and upon resolution of the reaction, reinitiation at a lower infusion rate and/or therapeutic administration of antihistamines, acetaminophen, and/or corticosteroids. For patients that do not tolerate the infusion following these interventions, REMICADE should be discontinued. During or following infusion, patients that have severe infusion-related hypersensitivity reactions should be discontinued from further REMICADE treatment. The management of severe infusion reactions should be dictated by the signs and symptoms of the reaction. Appropriate personnel and medication should be available to treat anaphylaxis if it occurs.

**REFERENCES:** 1. *Am J Respir Crit Care Med*. 2000;161:S221-S247. 2. See latest Centers for Disease Control guidelines and recommendations for tuberculosis testing in immunocompromised patients. 3. Gardam MA, Keystone EC, Menzies R, et al. Anti-tumor necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. *Lancet Infect Dis*. 2003;3:148-155. 4. Behladij K, Reyes F, Farcet JP, et al. Hepatosplenic  $\gamma$ -T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients. *Blood*. 2003;102(13):4261-4269.

© 2007 Centocor, Inc.  
Malvern, PA 19355, USA  
1-800-457-6399

License #1242  
Revised April 2007  
IN07515

# Does Birth Month Play a Role in BMD Later in Life?

BY NANCY WALSH

New York Bureau

LIVERPOOL, ENGLAND — Maternal exposure to sunlight in late pregnancy can have a beneficial influence on the offspring's bone mineral density in later life, Dr. Nicola J. Goodson said at the annual meeting of the British Society for Rheumatology.

"In the United Kingdom, the main dietary sources of vitamin D are fish and fortified margarine, but more than 90% of the vitamin is obtained by casual exposure to the sun, and because of the latitude the majority of the population is vitamin D deficient for much of the year," said Dr. Goodson of University Hospital Aintree, University of Liverpool (England).

Birth records and dual-energy x-ray absorptiometry (DXA) scan results were examined for 15,042 women and 2,160 men from the Morecambe Bay catchment district. The mean age was 62 years.

At the latitude of this district, 54 degrees north, the months with adequate sunlight are May through September. Patients therefore were categorized as having infant sunlight exposure if their birth months were between March and September and they could be expected to have at least 1 month of exposure to ultraviolet B light in the first 3 months of life. They were classified as antenatal exposure if their birth months were between May and November and they had at least 1 neonatal month of exposure to sunlight, said Dr. Goodson.

Overall, 51% of patients had BMD in the normal range. As expected, women

had lower mean T scores, at -1.7, than did men, at -0.91, she said.

Analysis of sunlight exposure in the first 3 months of life and normal BMD, after adjustment for age at the time of the DXA scan, found no significant association, with an odds ratio (OR) of 1.

In contrast, for those categorized as antenatal exposure, there was a modest association with normal bone mineral density in adulthood, with an OR of 1.16, Dr. Goodson said. Those patients who had antenatal sunlight exposure also were likely to have osteopenia or osteoporosis: Those who were osteopenic had a 12% reduced odds of antenatal exposure and those who were osteoporotic had a 19% reduced odds of antenatal exposure, she said.

These associations were only seen among women.

In a separate analysis for those whose DXA scans were done before age 50, there was no association of early life sunlight exposure in either men or women. However, in these younger patients there was a very strong association of early life, rather than antenatal, exposure with osteoporosis. "Those patients in the osteoporotic range had a 49% reduced odds of having a birth month that enabled antenatal exposure to UVB," she said.

In summary, she said, adult BMD was associated with birth month in this unselected DXA cohort.

"Maternal vitamin D levels should be optimized, particularly during the third trimester, either by diet or by safe UV exposure," Dr. Goodson said. ■

# New ACP Guideline Urges Osteoporosis Screening in Men

BY SHERRY BOSCHERT

San Francisco Bureau

Clinicians should assess older men for risk factors for osteoporosis and measure bone density by dual-energy x-ray absorptiometry if any risk factors are present, a new guideline from the American College of Physicians recommends.

How old is "older" is left open to interpretation and is one point of difference between the ACP guideline and guidelines issued by the National Osteoporosis Foundation (NOF) in February 2008.

The new NOF guidelines include screening and treatment in men as well as women, and recommend bone density testing in men aged 50-69 who have risk factors for osteoporosis and in all men aged 70 or older (RHEUMATOLOGY NEWS, May 2008, p. 1).

The ACP guidelines (Ann. Intern. Med. 2008;148:680-4) focus specifically on screening in men and notes the appropriate age at which to start risk assessment is uncertain. The medical evidence in the literature shows that by 65, at least 6% of men have osteoporosis proved by dual-energy x-ray absorptiometry (DXA), Dr. Amir Qaseem said in an interview.

The ACP plans to issue a separate new

guideline for treating osteoporosis in men in the near future, added Dr. Qaseem, lead author of the guideline and a senior medical associate for the ACP.

The main risk factors for osteoporosis in men are age older than 70, a body mass index of 25 kg/m<sup>2</sup> or less, weight loss greater than 10% of what would be expected, physical inactivity (no regular walking, climbing stairs, carrying heavy objects, housework, or gardening), corticosteroid use, androgen deprivation therapy, or previous fracture related to fragility, the report states.

The new ACP guideline is based on a systematic review of evidence published in 1990-2007 conducted by the federal Agency for Healthcare Research and Quality's evidence-based practice center in Southern California.

The prevalence of osteoporosis is estimated to be 7% in white, 5% in black, and 3% in Hispanic men, Dr. Qaseem noted. Over the next 15 years the rate of osteoporosis in U.S. men is expected to increase by half, with a doubling or tripling of hip fracture rates by 2040.

The prevalence of osteoporosis in Asian American men and other ethnic groups is unknown because of a lack of data. More research is needed, the guideline states. ■